Form 4: Outlook Therapeutics Director Julia Haller Awarded Stock Options

Director Julia Haller received stock options from Outlook Therapeutics under the company's equity incentive plan and non-employee director compensation policy.

Summary

• Julia Haller, a director at Outlook Therapeutics, received stock options on October 1, 2024, and October 3, 2024.
• The options were granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan.
• 56,636 options were granted at an exercise price of $5.22, vesting fully on October 1, 2025, subject to continuous service.
• 47,232 options were granted at an exercise price of $5.22, vesting fully on October 1, 2025, subject to continuous service.
• 12,082 options were granted at an exercise price of $5.25, vesting in four equal quarterly installments, subject to continuous service.
• The options are subject to acceleration upon a Change in Control, provided the Reporting Person provides continuous service.
• The 12,082 options were granted in lieu of $55,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.
• Acceleration upon a Change in Control provides additional security for the director.

Risks

• The value of the options is dependent on the future performance of the company's stock.
• The director must provide continuous service to fully vest the options.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the options.

Industry Context

Stock option grants are a common form of compensation for directors, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry, depending on company size, stage of development, and board responsibilities.
• Stock options are a standard component of director compensation, often vesting over a multi-year period to encourage long-term commitment.
• The specific terms of the option grants, such as the exercise price and vesting schedule, are generally benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• Shareholders: The option grants align the director's interests with those of shareholders, incentivizing value creation.
• Employees: The equity incentive plan may also benefit employees, fostering a sense of ownership and shared success.

Key Dates